

MYRIAD GENETICS INC
Form 10-Q
May 04, 2011
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2011

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to

Commission file number: 0-26642

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: MYRIAD GENETICS INC - Form 10-Q

Delaware (State or other jurisdiction of incorporation or organization)	87-0494517 (I.R.S. Employer Identification No.)
320 Wakara Way, Salt Lake City, UT (Address of principal executive offices)	84108 (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Check one:

Large accelerated filer <input checked="" type="checkbox"/>	Accelerated filer <input type="checkbox"/>
Non-accelerated filer <input type="checkbox"/> (Do not check if smaller reporting company)	Smaller reporting company <input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of April 29, 2011 the registrant had 85,735,872 shares of \$0.01 par value common stock outstanding.

Table of Contents

MYRIAD GENETICS, INC.

INDEX TO FORM 10-Q

	Page
PART I - Financial Information	
Item 1. Financial Statements	
<u>Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2011 and June 30, 2010</u>	3
<u>Condensed Consolidated Income Statements (Unaudited) for the three and nine months ended March 31, 2011 and 2010</u>	4
<u>Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended March 31, 2011 and 2010</u>	5
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	14
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	22
Item 4. <u>Controls and Procedures</u>	22
PART II - Other Information	
Item 1. <u>Legal Proceedings</u>	23
Item 1A. <u>Risk Factors</u>	23
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	24
Item 3. <u>Defaults Upon Senior Securities</u>	24
Item 4. <u>(Removed and Reserved)</u>	24
Item 5. <u>Other Information</u>	24
Item 6. <u>Exhibits</u>	24
<u>Signatures</u>	26

Table of Contents

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

<i>(In thousands, except per share amounts)</i>	Mar. 31, 2011	Jun. 30, 2010
Assets		
Current assets:		
Cash and cash equivalents	\$ 67,378	\$ 92,840
Marketable investment securities	293,846	310,388
Prepaid expenses	2,235	4,054
Trade accounts receivable, less allowance for doubtful accounts of \$4,200 at Mar. 31, 2011 and \$4,400 at Jun. 30, 2010	46,436	47,801
Deferred taxes	4,427	18,560
Other receivables	1,284	333
Total current assets	415,606	473,976
Equipment and leasehold improvements:		
Equipment	51,844	48,941
Leasehold improvements	16,438	16,332
	68,282	65,273
Less accumulated depreciation	46,939	42,012
Net equipment and leasehold improvements	21,343	23,261
Long-term marketable investment securities	90,267	85,154
Long-term deferred taxes	28,153	9,404
Other assets	1,911	2,052
Total assets	\$ 557,280	\$ 593,847
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 5,191	\$ 8,870
Accrued liabilities	18,181	18,596
Total current liabilities	23,372	27,466
Unrecognized tax benefits	9,448	8,800
Total liabilities	32,820	36,266
Stockholders' equity:		
Preferred stock, \$0.01 par value, authorized 5,000 shares, issued and outstanding no shares		
Common stock, \$0.01 par value, authorized 150,000 shares at Mar. 31, 2011 and Jun. 30, 2010, issued and outstanding 85,716 at Mar. 31, 2011 and 94,046 at Jun. 30, 2010	857	940
Additional paid-in capital	571,585	566,967
Accumulated other comprehensive income	100	139
Accumulated deficit	(48,082)	(10,465)
Total stockholders' equity	524,460	557,581

\$ 557,280 \$ 593,847

See accompanying notes to condensed consolidated financial statements (unaudited).

Table of Contents

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED INCOME STATEMENTS (UNAUDITED)

<i>(In thousands, except per share amounts)</i>	Three Months Ended		Nine Months Ended	
	Mar. 31, 2011	Mar. 31, 2010	Mar. 31, 2011	Mar. 31, 2010
Revenue	\$ 102,374	\$ 90,830	\$ 294,672	\$ 268,720
Costs and expenses:				
Cost of revenue	11,133	10,880	34,191	33,024
Research and development expense	6,667	5,885	18,520	16,620
Selling, general, and administrative expense	42,750	40,840	125,960	121,616
Total costs and expenses	60,550	57,605	178,671	171,260
Operating income	41,824	33,225	116,001	97,460
Other income (expense):				
Interest income	547	1,232	1,816	4,676
Other	(59)	23	(273)	94
Total other income	488	1,255	1,543	4,770
Income before income taxes	42,312	34,480	117,544	102,230
Income tax provision	14,372	1,229	42,874	3,177
Net income	\$ 27,940	\$ 33,251	\$ 74,670	\$ 99,053
Earnings per share:				
Basic	\$ 0.32	\$ 0.34	\$ 0.82	\$ 1.03
Diluted	\$ 0.31	\$ 0.33	\$ 0.80	\$ 1.00
Weighted average shares outstanding				
Basic	88,206	96,853	91,019	96,361
Diluted	90,127	99,674	92,846	99,521

See accompanying notes to condensed consolidated financial statements (unaudited).

Table of Contents

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<i>(In thousands)</i>	Nine Months Ended	
	Mar. 31, 2011	Mar. 31, 2010
Cash flows from operating activities:		
Net income	\$ 74,670	\$ 99,053
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	5,341	5,292
Loss on disposition of assets		367
Share-based compensation expense	18,715	16,973
Bad debt expense	12,337	13,737
Non-cash expense related to in-process research and development technology	1,500	
Deferred income taxes	39,591	
Unrecognized tax benefits	(348)	
Excess tax benefit from share-based compensation	(44,182)	
(Gain) loss on sale of marketable investment securities	35	(161)
Changes in operating assets and liabilities:		
Prepaid expenses	1,819	1,084
Trade accounts receivable	(10,972)	(17,238)
Other receivables	(951)	(591)
Accounts payable	(3,679)	(7,151)
Accrued liabilities	581	(2,801)
Net cash provided by operating activities	94,457	108,564
Cash flows from investing activities:		
Capital expenditures for equipment and leasehold improvements	(3,182)	(7,068)
Purchase of in-process research and development technology	(1,500)	
Purchase of other assets	(100)	(100)
Sale of intellectual property		300
Purchases of marketable investment securities	(338,963)	(331,041)
Proceeds from maturities and sales of marketable investment securities	350,293	249,270
Net cash provided by (used in) investing activities	6,548	(88,639)
Cash flows from financing activities:		
Net proceeds from common stock issued under share-based compensation plans	7,958	18,714
Excess tax benefit from share-based compensation	44,182	
Repurchase and retirement of common stock	(178,607)	
Net cash (used in) provided by financing activities	(126,467)	18,714
Net (decrease) increase in cash and cash equivalents	(25,462)	38,639
Cash and cash equivalents at beginning of period	92,840	63,510
Cash and cash equivalents at end of period	\$ 67,378	\$ 102,149

See accompanying notes to condensed consolidated financial statements (unaudited).

Table of Contents

MYRIAD GENETICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(1) Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the Company) in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (SEC). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Myriad Genetics Laboratories, Inc., and Myriad Therapeutics, Inc. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2010, included in the Company's Annual Report on Form 10-K for the year ended June 30, 2010. Operating results for the three and nine months ended March 31, 2011 may not necessarily be indicative of results to be expected for any other interim period or for the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(2) Marketable Investment Securities

The Company has classified its marketable investment securities as available-for-sale. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive income in stockholders' equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned.

Table of Contents

The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2011 and June 30, 2010 were as follows (in thousands):

	Amortized cost	Gross unrealized holding gains	Gross unrealized holding losses	Estimated fair value
At March 31, 2011:				
Cash and cash equivalents:				
Cash	\$ 23,710	\$	\$	\$ 23,710
Cash equivalents	43,668			43,668
Total cash and cash equivalents	67,378			67,378
Available-for-sale:				
Corporate bonds and notes	207,038	255	(25)	207,268
Federal agency issues	175,415	108	(28)	175,495
Auction rate securities	1,500		(150)	1,350
Total available-for-sale	383,953	363	(203)	384,113
Total cash, cash equivalents & available-for-sale	\$ 451,331	\$ 363	\$ (203)	\$ 451,491

	Amortized cost	Gross unrealized holding gains	Gross unrealized holding losses	Estimated fair value
At June 30, 2010:				
Cash and cash equivalents:				
Cash	\$ 23,314	\$	\$	\$ 23,314
Cash equivalents	69,525	1		69,526
Total cash and cash equivalents	92,839	1		92,840
Available-for-sale:				
Corporate bonds and notes	272,371	658	(339)	272,690
Federal agency issues	121,448	55	(1)	121,502
Auction rate securities	1,500		(150)	1,350
Total available-for-sale	395,319	713	(490)	395,542
Total cash, cash equivalents & available-for-sale	\$ 488,158	\$ 714	\$ (490)	\$ 488,382

Maturities of debt securities classified as available-for-sale are as follows at March 31, 2011 (in thousands):

	Amortized cost	Estimated fair value
Cash equivalents	\$ 43,668	\$ 43,668
Available-for-sale:		
Due within one year	287,232	287,507
Due after one year through three years	95,221	95,256

Edgar Filing: MYRIAD GENETICS INC - Form 10-Q

Due after three years	1,500	1,350
	\$ 427,621	\$ 427,781

Table of Contents**(3) Share-Based Compensation**

On December 3, 2010, the Company's shareholders approved the adoption of the 2010 Employee, Director and Consultant Equity Incentive Plan (the 2010 Plan). The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, and consultants and directors. Under the 2010 Plan, 3.5 million shares of common stock are authorized for issuance. The 2010 Plan also allows for the issuance of shares of common stock that are represented by options outstanding under the Company's 2003 Employee, Director and Consultant Option Plan (the 2003 Plan) and 2002 Amended and Restated Employee, Director and Consultant Stock Option Plan (the 2002 Plan), both of which have been terminated, that expire or are cancelled without delivery of shares of common stock on or after December 3, 2010, the date of stockholder approval of the 2010 Plan. As of March 31, 2011, approximately 14.1 million shares represented by options that remain outstanding under the 2002 Plan and 2003 Plan will transfer to the 2010 Plan if the options are cancelled or expire without delivery of the shares of stock by the Company.

The number of shares, terms, and vesting period are determined by the Compensation Committee of the Board of Directors for each equity award. Options generally vest ratably over four years and expire ten years from the date of grant. The exercise price of options granted is equivalent to the fair market value of the stock on the date of grant. The Company also has an Employee Stock Purchase Plan under which 2.0 million shares of common stock have been authorized and, as March 31, 2011, approximately 0.3 million shares are available for purchase by eligible employees. Any shares are issued twice yearly at the end of each six month offering period. During the three and nine months ended March 31, 2011, the Company issued approximately 0 and 0.1 million shares of common stock under the Employee Stock Purchase Plan.

A summary of the stock option activity for the nine months ended March 31, 2011 is as follows:

	Number of shares	Weighted average exercise price
Options outstanding at June 30, 2010	14,116,838	\$ 18.03
Options granted	3,039,040	17.48
Less:		
Options exercised	(714,389)	9.56
Options canceled or expired	(821,221)	26.41
Options outstanding at March 31, 2011	15,620,368	17.87

As of March 31, 2011, options to purchase 8.9 million shares were vested and exercisable at a weighted average price of \$15.29. As of March 31, 2011, there was approximately \$42.4 million of total unrecognized share-based compensation cost related to share-based awards granted under the Company's plans that will be recognized over a weighted-average period of 2.6 years.

Table of Contents

Share-based compensation expense recognized and included in the consolidated income statements was allocated as follows (*in thousands*):

	Three months ended Mar. 31,		Nine months ended Mar. 31,	
	2011	2010	2011	2010
Molecular diagnostic cost of revenue	\$ 301	\$ 255	\$ 897	\$ 740
Research and development expense	865	923	2,926	2,793
Selling, general, and administrative expense	5,059	3,799	14,892	13,440
Total share-based compensation expense	\$ 6,225	\$ 4,977	\$ 18,715	\$ 16,973

(4) Stockholders Equity
Comprehensive Income

The components of the Company's comprehensive income are as follows:

<i>(In thousands)</i>	Three months ended Mar. 31,		Nine months ended Mar. 31,	
	2011	2010	2011	2010
Net income	\$ 27,940	\$ 33,251	\$ 74,670	\$ 99,053
Unrealized gain (loss) on available-for-sale securities, net of tax	1	(699)	(39)	(1,613)
Comprehensive income	\$ 27,941	\$ 32,552	\$ 74,631	\$ 97,440

Stock Repurchase Program

On May 4, 2010, the Company announced that its board of directors authorized the repurchase of \$100 million of the Company's outstanding common stock. On August 31, 2010, the Company announced that its board of directors authorized the repurchase of an additional \$100 million of the Company's outstanding common stock. In February 2011, the Company completed the May and August 2010 share repurchase programs.

On March 1, 2011, the Company announced that its board of directors authorized a third plan to repurchase an additional \$100 million of the Company's outstanding common stock. In connection with this stock repurchase authorization, the Company entered into an accelerated share repurchase program (ASR program) with J.P. Morgan to repurchase \$50 million of the Company's common stock. The number of shares to be ultimately repurchased by the Company under the ASR program will be based on the average daily volume-weighted average price of its common stock during a specified period less a predetermined discount per share. The actual number of shares repurchased will be determined at the completion of the ASR program. The Company expects all ASR program purchases be completed by June 2011. After making the initial payment of \$50 million, the Company is not obligated to deliver any cash or shares to J.P. Morgan except in certain limited circumstances in which case the method of delivery (cash or shares of the Company's common stock) would be at the Company's discretion. As of March 31, 2011, the Company has repurchased and retired approximately 2.6 million shares of the Company's common stock under the ASR program.

The Company accounted for the accelerated share repurchase as two separate transactions: (a) as shares of common stock acquired in a treasury transaction recorded on the transaction date and (b) as a forward contract indexed to the Company's common stock. As such, the Company accounted for the approximate 2.6 million shares that it received as a repurchase of its common stock and retired those shares immediately for net income per share purposes. The company has determined that the forward contract indexed to the Company's common stock met all the applicable criteria for equity classification, and therefore the contract was not accounted for as a derivative under applicable accounting guidance.

Table of Contents

The remaining \$50 million from the share repurchase program announced in March 2011 will be made through open market or privately negotiated purchases as determined by the Company. The Company expects to complete the share repurchase on or before December 31, 2011.

During the three and nine months ended March 31, 2011, the Company repurchased and retired approximately 4.5 million and 9.1 million shares of its common stock and has repurchased and retired an accumulated 13.1 million shares under all the share repurchase programs. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases the Company reduced common stock and additional paid-in capital by an aggregate of \$32.7 million and \$53.5 million and charged \$55.4 million and \$96.5 million to retained earnings for the three and nine months ended March 31, 2011, respectively.

(5) Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of the Company's common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of the Company's common stock, including common stock equivalents outstanding. Certain common shares consisting of stock options that would have an antidilutive effect were not included in the diluted earnings per share attributable to common stockholders for the three and nine months ended March 31, 2011 and 2010.

The following is a reconciliation of the denominators of the basic and diluted earnings per share computations (*in thousands*):

	Three months ended Mar. 31,		Nine months ended Mar. 31,	
	2011	2010	2011	2010
Denominator:				
Weighted-average shares outstanding used to compute basic earnings per share	88,206	96,853	91,019	96,361
Effect of dilutive stock options	1,921	2,821	1,827	3,160
Weighted-average shares outstanding and dilutive securities used to compute diluted earnings per share	90,127	99,674	92,846	99,521

For the three and nine months ended March 31, 2011, there were outstanding potential common equivalent shares of 8,766,588 and 8,648,261, compared to 6,272,598 and 5,845,628 in the same period in 2010, which were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common equivalent shares may be dilutive to future diluted earnings per share.

(6) Segment and Related Information

The Company's business units from continuing operations have been aggregated into two reportable segments: (i) genetics and (ii) molecular diagnostics. The genetics segment is focused on research and development of molecular genetic products and technologies and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing to determine predispositions to common diseases that aid in personalizing medical treatments, and determine the aggressiveness of certain diseases.

The Company evaluates segment performance based on results from operations before interest income and expense and other income and expense.

Table of Contents

<i>(In thousands)</i>	Genetics	Molecular diagnostics	Total
Three months ended Mar. 31, 2011:			
Revenue	\$	\$ 102,374	\$ 102,374
Depreciation and amortization	513	1,287	1,800
Segment operating income (loss)	(12,571)	54,395	41,824
Three months ended Mar. 31, 2010:			
Revenue		90,830	90,830
Depreciation and amortization	588	1,191	1,779
Segment operating income (loss)	(10,768)	43,993	33,225
Nine months ended Mar. 31, 2011:			
Revenue		294,672	294,672
Depreciation and amortization	1,484	3,857	5,341
Segment operating income (loss)	(35,276)	151,277	116,001
Nine months ended Mar. 31, 2010:			
Revenue	\$	\$ 268,720	\$ 268,720
Depreciation and amortization	1,645	3,647	5,292
Segment operating income (loss)	(32,459)	129,919	97,460

<i>(In thousands)</i>	Three months ended Mar. 31,		Nine months ended Mar. 31,	
	2011	2010	2011	2010
Total operating income for reportable segments	\$ 41,824	\$ 33,225	\$ 116,001	\$ 97,460
Interest income	547	1,232	1,816	4,676
Other	(59)	23	(273)	94
Income tax provision	14,372	1,229	42,874	3,177
Net income	\$ 27,940	\$ 33,251	\$ 74,670	\$ 99,053

(7) Fair Value Measurements

The fair value of the Company's financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:

Level 1 quoted prices in active markets for identical assets and liabilities.

Level 2 observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company's marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.

Level 3 unobservable inputs.

Table of Contents

The substantial majority of the Company's financial instruments are valued using quoted prices in active markets or based on other observable inputs. The following table sets forth the fair value of our financial assets that the Company re-measured:

<i>(In thousands)</i> at March 31, 2011	Level 1	Level 2	Level 3	Total
Money market funds (a)	\$ 5,069	\$	\$	\$ 5,069
Corporate bonds and notes		245,866		245,866
Federal agency issues		175,495		175,495
Auction rate securities			1,350	1,350
Total	\$ 5,069	\$ 421,361	\$ 1,350	\$ 427,780

<i>(In thousands)</i> at June 30, 2010	Level 1	Level 2	Level 3	Total
Money market funds (a)	\$ 29,929	\$	\$	\$ 29,929
Corporate bonds and notes		296,987		296,987
Federal agency issues		136,802		136,802
Auction rate securities			1,350	1,350
Total	\$ 29,929	\$ 433,789	\$ 1,350	\$ 465,068

(a) Money market funds are primarily comprised of government and agency obligations and accrued interest

As of March 31, 2011, the Company held \$1.4 million of investments which were measured using unobservable (Level 3) inputs. These investments represent less than 1% of our investments portfolio and were classified as Level 3 assets as of March 31, 2011. Our Level 3 assets consist of auction rate securities and the value is determined based on market quotes of comparable securities. There were no changes in the composition or estimated fair value of our Level 3 financial assets for the period ended March 31, 2011.

(8) Commitments and Contingencies

The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company's consolidated financial position, operating results, or cash flows.

(9) Income Taxes

In order to determine the Company's quarterly provision for income taxes, it used an estimated annual effective tax rate, which is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rates from quarter to quarter.

Income tax expense for the three and nine months ended March 31, 2011 was \$14.4 million and \$42.9 million, or approximately 34% and 36% of pre-tax income, compared to \$1.2 million and \$3.2 million income tax expense for the three and nine months ended March 31, 2010. The effective tax rate for the three and nine months ended March 31, 2011 differs from the U.S. federal statutory rate of 35% primarily due to state income taxes. Income tax expense for the three and nine months ended March 31, 2010 consisted of alternative minimum tax and state tax liabilities.

The Company files U.S. and state income tax returns in jurisdictions with various statutes of limitations. The Company's consolidated federal tax return and any significant state tax returns are not currently under examination.

Table of Contents

(10) Asset Acquisition

On December 8, 2010, the Company acquired the proprietary technology for the diagnosis and prognosis of malignant melanoma using genetic markers from Melanoma Diagnostics, Inc. Under the terms of the agreement, the Company purchased various in-process research and development technology and rights for an upfront fee of \$1.5 million, which it immediately expensed. The asset purchase agreement also requires the Company to pay contingent consideration based upon any future commercial success of the tests derived from the purchased technology.

(11) Subsequent Event

On April 27, 2011, the Company entered into an agreement with Rules Based Medicine (RBM) to acquire all of the outstanding shares of RBM for \$80 million in cash.

The Company is in the process of obtaining Hart, Scott, Redino antitrust approval from the Federal Trade Commission and finalizing the allocation of the purchase price among the assets acquired and the liabilities assumed from the acquisition.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

We are a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine products. We believe that the future of medicine lies in a shift from a treatment paradigm to a prevention paradigm. By understanding the genetic basis of disease, we believe that individuals who have a greater risk of developing disease can be identified and physicians can use this information to improve patient outcomes and better manage patient healthcare. We employ a number of proprietary technologies that help us to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset, progression and treatment of disease. We use this information to guide the development of new molecular diagnostic products that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and help guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Our goal is to provide physicians with this critical information that may guide the healthcare management of their patients to prevent disease, delay the onset of disease, or diagnose the disease at an earlier stage when it is more treatable. We are also committed to assisting the physician in managing their patient's healthcare to ensure that they receive the most appropriate therapy based on the patient's individual genetic makeup and the specific cause of their disease.

We offer nine commercial molecular diagnostic products, including five predictive medicine products, three personalized medicine products, and a prognostic medicine product. In December 2010 we announced the launch of our ninth molecular diagnostic product, Panexia, a predictive medicine test for the genetic predisposition of pancreatic cancer. We market these products through our own 315-person sales force in the United States and are currently formulating our plans for our international expansion. Revenue was \$102.4 million and \$294.7 million for the three and nine months ended March 31, 2011, an increase of approximately 13% and 10% over revenues of \$90.8 million and \$268.7 million for the same period in the prior year.

The nine commercial molecular diagnostic products that we offer are:

*BRCA*Analysis[®], our predictive medicine product for hereditary breast and ovarian cancer;

COLARIS[®], our predictive medicine product for hereditary colorectal and uterine cancer;

COLARIS AP[®], our predictive medicine product for hereditary colon cancer;

MELARIS[®], our predictive medicine product for hereditary melanoma;

Theraguide[®] 5-FU, our personalized medicine product for chemotherapy toxicity to 5-FU;

Prezeon , our personalized medicine product to assess PTEN status for disease progression and drug response;

OnDose[®], our personalized medicine product to measure chemotherapy exposure to 5-FU;

Prolaris , our prognostic medicine product for prostate cancer; and

Panexia , our predictive medicine product for pancreatic cancer.

Edgar Filing: MYRIAD GENETICS INC - Form 10-Q

During December 2010, we acquired proprietary technology for the diagnosis and prognosis of malignant melanoma using genetic marker technology from Melanoma Diagnostics, Inc. The tests that may be developed from the acquired technology may provide physicians with important information in the differential diagnosis of melanoma from otherwise benign moles, and in understanding the aggressiveness of the patient's disease. Under the agreement, we have the right to commercialize all tests derived from the technology on a worldwide basis in exchange for an upfront payment of \$1.5 million and contingent payments based upon the commercial success of the products. The upfront payment was fully expensed as research and development during the quarter ended December 31, 2010.

Table of Contents

During the three and nine months ended March 31, 2011, we devoted substantially all of our resources to supporting our molecular diagnostic products, as well as to the research and development of future molecular diagnostic product candidates. We are also formulating our plans for future international expansion. We have two reportable operating segments—genetics and molecular diagnostics. See Note 6—Segment and Related Information in the notes to our condensed consolidated financial statements (unaudited) for information regarding these operating segments.

We incurred research and development expenses of \$6.7 million and \$18.5 million for the three and nine months ended March 31, 2011, compared to \$5.9 million and \$16.6 million for the three and nine months ended March 31, 2010. Our research and development expenses include costs incurred in maintaining and improving our nine current molecular diagnostic products and costs incurred for the discovery, development and validation of our pipeline of molecular diagnostic product candidates. Our sales and marketing expenses and general and administrative expenses include costs associated with building our molecular diagnostic business. We expect that these costs will fluctuate from quarter to quarter and that such fluctuations may be substantial.

For the three and nine months ended March 31, 2011, we had net income of \$27.9 million and \$74.7 million and diluted earnings per share of \$0.31 and \$0.80. During the fiscal year the net income and earnings per share results included income tax expense of \$14.4 million and \$42.9 million, respectively. For the three and nine months ended March 31, 2010 we had net income of \$33.3 million and \$99.1 million and diluted earnings per share of \$0.33 and \$1.00 that included income tax expense of \$1.2 million and \$3.2 million, respectively. The increase in the current period income tax expense was primarily due to the application of our effective tax rate of approximately 34% and 36% of earnings while income tax expense for the same periods in 2010 was comprised solely of alternative minimum tax and state tax liabilities. Due to the utilization of net operating loss carryforwards to offset our taxes payable, we expect our actual cash payments for income taxes to be minimal compared to our current income tax expense.

On May 4, 2010, we announced that our board of directors had authorized the repurchase of \$100 million of our outstanding common stock. On August 31, 2010, we announced that our board of directors had authorized the repurchase of an additional \$100 million of our outstanding common stock. As of February 28, 2011, we had completed the May and August 2010 share repurchase programs. On March 1, 2011, we announced that our board of directors authorized a third plan to repurchase an additional \$100 million of our outstanding common stock. In connection with this stock repurchase authorization, we entered into an accelerated share repurchase agreement (ASR program) with J.P. Morgan to repurchase \$50 million of our common stock. The number of shares to be ultimately repurchased under the ASR program will be based on the average daily volume-weighted average price of our common stock during a specified period less a predetermined discount per share. As of March 31, 2011 we have repurchased and retired approximately 2.6 million shares of our common stock under the ASR program for an aggregate purchase price of \$50 million. We expect all ASR program purchases to be completed by June 30, 2011. The remaining \$50 million from the share repurchase program announced in March 2011 will be made through open market or privately negotiated purchases as determined by us. We expect to complete this portion of the share repurchase program on or before December 31, 2011. See also Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds—Issuer Purchases of Equity Securities.

On April 27, 2011, we entered into an agreement with Rules Based Medicine (RBM) to acquire all of the outstanding shares of RBM for \$80 million in cash. We believe that this acquisition represents an attractive opportunity because of RBM's (i) strong product pipeline in the psychiatric, infections and inflammatory disease areas, (ii) leadership in the companion diagnostic fields, and (iii) proprietary, multiplex immunoassay technology. We anticipate the acquisition will close on or before May 31, 2011.

Table of Contents

We are in the process of obtaining Hart, Scott, Redino antitrust approval from the Federal Trade Commission and finalizing the allocation of the purchase price among the assets acquired and the liabilities assumed from the acquisition.

Critical Accounting Policies

Critical accounting policies are those policies which are both important to the presentation of a company's financial condition and results and require management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are as follows:

revenue recognition;

allowance for doubtful accounts;

share-based payment expense; and

income taxes.

Revenue Recognition. Revenue includes revenue from the sale of molecular diagnostic products and related marketing agreements, and is recorded at the invoiced amount net of any discounts or contractual allowances. Revenue is recognized upon completion of the test, communication of results, and when collectability is reasonably assured.

Allowance for Doubtful Accounts. Trade accounts receivable are comprised of amounts due from sales of our molecular diagnostic products, which are recorded net of any discounts or contractual allowances. We analyze collectability of trade accounts receivable and consider historic experience, customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms when evaluating the adequacy of the allowance for doubtful accounts. We periodically evaluate and adjust the allowance for doubtful accounts when trends or significant events indicate that a change in estimate is appropriate. Such changes in estimate could materially affect our results of operations or financial position; however, to date these changes have not been material. It is possible that we may need to adjust our estimates in future periods.

As of March 31, 2011 and June 30, 2010, if a hypothetical ten percent increase in our allowance for doubtful accounts were to occur, this would result in additional bad debt expense and an increase to our allowance for doubtful accounts of \$420,000 and \$440,000, respectively.

Share-Based Payment Expense. We recognize share-based equity compensation in our consolidated statements of operations at the grant-date fair value of our stock options and other equity-based compensation. The determination of grant-date fair value is estimated using an option-pricing model, which includes variables such as the expected volatility of our share price, the exercise behavior of our employees, interest rates, and dividend yields. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material increases to the valuation of options granted in future periods and increases in the expense recognized for share-based payments.

Income Taxes. Our income tax provision is based on income before taxes and is computed using the liability method in accordance with ASC 740 *Income Taxes*. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using tax rates projected to be in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations, or the expected results from any future tax examinations. Various internal and external factors may have favorable or unfavorable effects on our future provision for income taxes. Those factors include, but are not limited to, changes in tax laws, regulations and/or rates, the results of any future tax examinations, changing interpretations of existing tax laws or regulations, changes in estimates of prior years' items, past levels of R&D spending, acquisitions, changes in our corporate structure, and changes in overall levels of income before taxes all of which may result in periodic revisions to our provision for income taxes.

Table of Contents

Developing our provision for income taxes, including our effective tax rate and analysis of potential uncertain tax positions, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowance we deem necessary to offset deferred tax assets. During the fourth quarter of the fiscal year ended June 30, 2010, we determined that a valuation allowance was not required for our deferred tax assets because we have established a sufficient history of taxable income from operations. However, if we do not maintain taxable income from operations in future periods, we may increase the valuation allowance for our deferred tax assets and record material adjustments to our income tax expense. Our judgment and tax strategies are subject to audit by various taxing authorities. While we believe we have provided adequately for our uncertain income tax positions in our consolidated financial statements, adverse determination by these taxing authorities could have a material adverse effect on our consolidated financial condition, results of operations or cash flows. Interest and penalties on income tax items are included as a component of overall income tax expense.

Results of Operations for the Three Months Ended March 31, 2011 and 2010

Revenue for the three months ended March 31, 2011 was \$102.4 million, compared to \$90.8 million for the same three months in 2010. Of this 13% increase in revenue, approximately 8% is attributable to increased testing volume and approximately 5% is attributable to price increases. We believe that increased sales, marketing, and education efforts resulted in wider acceptance of our products by the medical community and increased patient testing volumes. While the markets in which we operate are still experiencing high unemployment, the economy appears to be improving and physician office visits were stable during the three months ended March 31, 2011. However, there can be no assurance that molecular diagnostic revenue will continue to increase or remain at current levels.

Our revenues consist predominately of sales of our molecular diagnostic products. Revenues of our products for the three months ended March 31, 2011 and 2010 were as follows:

<i>(In thousands)</i>	Three months ended Mar. 31,	
	2011	2010
Revenues:		
BRACAnalysis	\$ 90,303	\$ 79,802
COLARIS & COLARIS AP	7,414	6,949
Other	4,657	4,079
Total Revenues	\$ 102,374	\$ 90,830

Our sales force is focused on two major markets, oncology and women's health. Sales of molecular diagnostic products in each market for the three months ended March 31, 2011 and 2010 were as follows:

<i>(In thousands)</i>	Three months ended Mar. 31,	
	2011	2010
Revenues:		
Oncology	\$ 72,988	\$ 64,314
Women's Health	29,267	26,390
Other	119	126
Total Revenues	\$ 102,374	\$ 90,830

Table of Contents

Cost of revenue is comprised primarily of salaries and related personnel costs, laboratory supplies, royalty payments, equipment costs and facilities expense. Cost of revenue for the three months ended March 31, 2011 was \$11.1 million, compared to \$10.9 million for the same three months in 2010. This increase in molecular diagnostic cost of revenue is primarily due to an increase in testing volumes. Our gross profit margin was 89% for the three months ended March 31, 2011 compared to 88% for the same period ended March 31, 2010. Our gross profit margins may fluctuate from quarter to quarter based on the introduction of new molecular diagnostic products, price increases of existing products, changes in our costs associated with such products, new technologies and operating systems to integrate into our molecular diagnostic laboratory and costs associated with establishing any additional laboratories outside the United States. There can be no assurance that gross profit margins will continue to increase or remain at current levels.

Research and development expenses are comprised primarily of salaries and related personnel costs, laboratory supplies, clinical trial costs for molecular diagnostic products in development, and equipment and facility costs. Research and development expenses incurred during the three months ended March 31, 2011 were \$6.7 million compared to \$5.9 million for same three months in 2010. This increase of 13% was primarily due to increased research and development associated with clinical studies to support our existing molecular diagnostic products, and internal molecular diagnostic product discovery. These increases were offset by a decrease in lab supply costs. We expect our research and development expenses will increase over the next several years as we continue to develop our product pipeline and expand our offerings of molecular diagnostic products.

Selling, general and administrative expenses consist primarily of salaries, commissions and related personnel costs for sales, marketing, customer service, billing and collection, executive, legal, finance and accounting, information technology, human resources, and allocated facilities expenses. Selling, general and administrative expenses for the three months ended March 31, 2011 were \$42.8 million, compared to \$40.8 million for the same three months in 2010. The increase in selling, general and administrative expense of 5% was due primarily to:

an increase in share-based compensation expense of approximately \$1.3 million;

an increase in administrative costs of approximately \$1.1 million to evaluate our future international expansion and to support our 13% revenue growth; and

an increase in sales and marketing expense of approximately \$0.2 million to support our 13% revenue growth;

offset in part by a decrease in bad debt expense of approximately \$0.6 million due to improved collection efforts.

We expect our selling, general and administrative expenses will continue to fluctuate depending on the number and scope of any new molecular diagnostic product launches, our efforts in support of our existing molecular diagnostic products and our continued international expansion efforts.

Interest income for the three months ended March 31, 2011 was \$0.5 million, compared to \$1.2 million for the same three months in 2010, a decrease of 56%. The decrease was due primarily to lower market interest rates during the 2011 period.

Income tax expense for the three months ended March 31, 2011 was \$14.4 million, for an effective rate of approximately 34%, compared to income tax expense of \$1.2 million in the 2010 period. Income tax expense for the three months ended March 31, 2010 consisted of alternative minimum tax and state tax liabilities, compared to income tax expense for the current quarter that is based on our estimated annual effective tax rate for the full fiscal year ending June 30, 2011 adjusted by discrete items recognized during the period. Our annual effective tax rate differs from the U.S. federal statutory rate of 35% primarily due to state income taxes. Certain significant or unusual items are separately recognized during the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. Due to the utilization of net operating loss carryforwards that offset our taxes payable, our current income tax expense in fiscal 2011 is significantly higher than our actual cash paid for income taxes.

Table of Contents**Results of Operations for the Nine Months Ended March 31, 2011 and 2010**

Revenue for the nine months ended March 31, 2011 was \$294.7 million, compared to \$268.7 million for the same nine months in 2010. Of this 10% increase in revenue, approximately 6% is attributable to increased testing volume and approximately 4% is attributable to price increases.

Revenues of our products for the nine months ended March 31, 2011 and 2010 were as follows:

<i>(In thousands)</i>	Nine months ended Mar. 31,	
	2011	2010
Revenues:		
BRACAnalysis	260,156	\$ 237,273
COLARIS & COLARIS AP	21,543	20,038
Other	12,973	11,409
Total Revenues	294,672	\$ 268,720

Our sales force is focused on two major markets, oncology and women's health. Sales of molecular diagnostic products in each market for the nine months ended March 31, 2011 and 2010 were as follows:

<i>(In thousands)</i>	Nine months ended Mar. 31,	
	2011	2010
Revenues:		
Oncology	\$ 208,379	\$ 193,566
Women's Health	86,084	74,962
Other	209	192
Total Revenues	\$ 294,672	\$ 268,720

Cost of revenue for the nine months ended March 31, 2011 was \$34.2 million, compared to \$33.0 million for the same nine months in 2010. This increase in molecular diagnostic cost of revenue is primarily due to an increase in testing volumes. Our gross profit margin was 88% for the nine months ended March 31, 2011 and 2010. Our gross profit margins may fluctuate from quarter to quarter based on the introduction of any new molecular diagnostic products, price increases of existing products, changes in our costs associated with such products, new technologies and operating systems integrated into our molecular diagnostic laboratory, and costs associated with establishing any additional laboratories outside the United States. There can be no assurance that gross profit margins will continue to increase or remain at current levels.

Research and development expenses incurred during the nine months ended March 31, 2011 were \$18.5 million compared to \$16.6 million for same nine months in 2010. This increase of 11% was primarily due to increased research and development associated with clinical studies to support our existing molecular diagnostic products, internal molecular diagnostic product discovery and development, and the purchase of in-process research and development technology. These increases were offset by a decrease in lab supply costs.

Table of Contents

Selling, general and administrative expenses for the nine months ended March 31, 2011 were \$126.0 million, compared to \$121.6 million for the same nine months in 2010. The increase in selling, general and administrative expense of 4% was due primarily to:

an increase in consulting administrative costs of approximately \$2.9 million to support planning or our international expansion;

an increase in sales and marketing expense of approximately \$1.4 million to support our 10% revenue growth; and

an increase in share-based compensation expense of approximately \$1.5 million;

offset in part by a decrease in bad debt expense of approximately \$1.4 million due to improved collection efforts.

We expect our selling, general and administrative expenses will continue to fluctuate depending on the number and scope of any new molecular diagnostic product launches, our efforts in support of our existing molecular diagnostic products, and our continued international expansion efforts.

Interest income for the nine months ended March 31, 2011 was \$1.8 million, compared to \$4.7 million for the same nine months in 2010, a decrease of 61%. The decrease was due primarily to lower market interest rates during the 2010 period.

Income tax expense for the nine months ended March 31, 2011 was \$42.9 million, for an effective rate of approximately 36%, compared to income tax expense of \$3.2 million in the 2010 period. Income tax expense for the nine months ended March 31, 2010 consisted of alternative minimum tax and state tax liabilities, compared to income tax expense for the current nine month period that is based on our estimated annual effective tax rate for the full fiscal year ending June 30, 2011 adjusted by discrete items recognized during the period. Our annual effective tax rate differs from the U.S. federal statutory rate of 35% primarily due to state income taxes. Certain significant or unusual items are separately recognized during the quarter during in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. Due to the utilization of net operating loss carryforwards that offset our taxes payable, our current income tax expense in fiscal 2011 is significantly higher than our actual cash paid for income taxes.

Liquidity and Capital Resources

Cash, cash equivalents, and marketable investment securities decreased \$36.9 million, or 8%, to \$451.5 million at March 31, 2011 from \$488.4 million at June 30, 2010. This decrease was primarily attributed to purchasing \$178.6 million of our common stock under our share repurchase programs, expenditures for our internal research and development programs, and purchases of technology and capital assets, which was offset by our increased collections from our molecular diagnostic sales.

Net cash provided by operating activities was \$94.5 million during the nine months ended March 31, 2011, compared to \$108.6 million provided by operating activities during the same nine months in 2010. Our net income was reduced by non-cash charges in the form of share-based compensation and depreciation and amortization which totaled \$31.0 million during the nine months ended March 31, 2011. Accounts receivable increased by \$11.0 million primarily due to an increase in our sales. Accrued liabilities and accounts payable decreased by \$1.0 million and \$3.7 million, respectively, between June 30, 2010 and March 31, 2011, primarily due to payments of sales and marketing expenses associated with our current direct to consumer (DTC) campaign.

Our investing activities provided cash of \$6.5 million during the nine months ended March 31, 2011 and used cash \$88.6 million during the same nine months in 2010. Investing activities were comprised primarily of purchases and sales and maturities of marketable investment securities and the purchase of in-process research and development technology. Capital expenditures for equipment and facilities for the nine months ended March 31, 2011 were \$3.2 million.

Financing activities used cash of \$126.2 million during the nine months ended March 31, 2011 and provided cash of \$18.7 million in the same nine months in 2010. Cash utilized in financing activities during the nine months ended March 31, 2011 was primarily due to the purchase of \$178.6 million of our common stock through our share repurchase programs, partially offset by \$8.0 million from cash provided by the exercise of stock options and \$44.2 million from excess tax benefits received from share based compensation.

Table of Contents

We believe that with our existing capital resources and expected net cash to be generated from sales of our molecular diagnostic products, we will have adequate funds to maintain our current and planned operations for at least the next three years, although no assurance can be given that changes will not occur that would consume available capital resources before such time and we may need or want to raise additional financing within this period of time. Our future capital requirements, cash flows, and results of operations could be affected by and will depend on many factors that are currently unknown to us, including:

failure to sustain revenue growth or margins in our molecular diagnostic business;

termination of the licenses underlying our molecular diagnostic products or failure to enter into product or technology licensing or other arrangements favorable to us;

delays or other problems with operating our laboratory facilities;

the costs and expenses incurred in supporting our existing molecular diagnostic products and expanding into foreign markets;

the progress, results and cost of developing and launching additional molecular diagnostic products for our molecular diagnostic business;

potential business development activities and acquisitions, such as our recently announced acquisition of RBM;

changes in the government regulatory approval process for our products;

the progress, results and costs of our international expansion efforts;

the costs, timing, outcome, and enforcement of any regulatory review of our existing or future molecular diagnostic products;

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related claims;

the costs, timing and outcome of any litigation against us;

the introduction of technological innovations or new commercial products by our competitors;

changes in intellectual property laws covering our molecular diagnostic products and patents or enforcement in the United States and foreign countries;

changes in the governmental or private insurers reimbursement levels for our products;

changes in structure of the healthcare system or healthcare payment systems; and

the impact of current economic conditions and job loss resulting in fewer doctor visits and loss of employer provided insurance coverage.

Effects of Inflation

We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented.

Certain Factors That May Affect Future Results of Operations

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as may, anticipate, estimate, expects, projects, intends, plans, believes and words and terms of similar substance used in with any discussion of future operating or

Table of Contents

financial performance, identify forward-looking statements. All forward-looking statements are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic products may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of the United States; the risk that we may be unable to develop or successfully commercialize additional molecular diagnostic products; the risk that licenses to the technology underlying our molecular diagnostic products and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our products; risks related to regulatory developments or enforcement in the United States and foreign countries and in particular changes in the structure of healthcare payment systems; risks related to our ability to obtain new corporate collaborations and acquire new technologies or businesses on satisfactory terms, if at all; the development of competing products and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our products; the risk of patent-infringement and invalidity claims; challenges to intellectual property rights underlying our products or changes in intellectual property laws; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual Report on Form 10-K for the year ended June 30, 2010, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in our market risk during the nine months ended March 31, 2011 compared to the disclosures in Part II, Item 7A of our Annual Report on Form 10-K for the year ended June 30, 2010, which is incorporated by reference herein.

Item 4. Controls and Procedures

- (a) *Evaluation of Disclosure Controls and Procedures.* Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

- (b) *Changes in Internal Controls.* There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - Other Information

Item 1. Legal Proceedings

There have been no material changes to the legal proceedings included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2010.

Item 1A. Risk Factors

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2010, except as set forth in our Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 1, 2010 (File No. 0-26642) and as follows:

Risks Related to Our Business and Our Strategy

We may acquire technologies, assets or other businesses that could cause us to incur significant expense and expose us to a number of unanticipated operational and financial risks.

In addition to organic growth, we intend to continue to pursue growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities, expand our geographic market, add experienced management personnel and increase our product offerings. However, we may be unable to implement this growth strategy if we cannot identify suitable acquisition candidates, reach agreement on potential acquisitions on acceptable terms, successfully integrate personnel or assets that we acquire or for other reasons. Our acquisition efforts may involve certain risks, including:

we may have difficulty integrating operations and systems;

key personnel and customers of the acquired company may terminate their relationships with the acquired company as a result of the acquisition;

we may not be successful in launching new molecular diagnostic products, or if those products are launched they may not prove successful in the market place;

we may experience additional financial and accounting challenges and complexities in areas such as tax planning and financial reporting;

we may assume or be held liable for risks and liabilities, including for environmental-related costs, as a result of our acquisitions, some of which we may not discover during our due diligence;

we may incur significant additional operating expenses;

our ongoing business may be disrupted or receive insufficient management attention; and

we may not be able to realize synergies, the cost savings or other financial and operational benefits we anticipated, or such synergies, savings or benefits may take longer than we expected.

Edgar Filing: MYRIAD GENETICS INC - Form 10-Q

The process of negotiating acquisitions and integrating acquired products, services, technologies, personnel or businesses might result in operating difficulties and expenditures and might require significant management attention that would otherwise be available for ongoing development of our business, whether or not any such transaction is ever consummated. Moreover, we might never realize the anticipated benefits of any acquisition. Future acquisitions could result in the use of our available cash and marketable securities, potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities, or impairment expenses related to goodwill, and impairment or amortization expenses related to other intangible assets, which could harm our financial condition. In addition, if we are unable to integrate any acquired businesses, products or technologies effectively, our business, financial condition and results of operations may be materially adversely affected.

In December 2010, we acquired technology from Melanoma Diagnostics, Inc., and in April 2011, we acquired Rules-Based Medicine, Inc. There can be no assurance that we will be able to successfully integrate these acquisitions or develop or commercialize products based on the acquired technologies, or that we will be able to successfully integrate any other companies, products or technologies that we acquire.

Table of Contents**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.****Issuer Purchases of Equity Securities**

On May 4, 2010, we announced a plan to repurchase up to \$100 million of the Company's common stock. On August 31, 2010, we announced that our board of directors authorized the repurchase of an additional \$100 million of our common stock. During February 2011, we completed the second share repurchase program. On March 1, 2011, we announced a third plan to repurchase an additional \$100 million of our outstanding common stock. The details of the activity during the third fiscal quarter were as follows:

Period	(a) Total Number of Shares Purchased	(b) Average Price Paid per Share	(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	(d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
January 1, 2011 to January 31, 2011	492,924	\$ 19.92	492,294	\$ 28,251,365
February 1, 2011 to February 28, 2011	1,431,537	19.73	1,431,537	
March 1, 2011 to March 31, 2011	2,568,410	19.47	2,568,410	50,000,000
Total	4,492,871	\$ 19.60	4,492,241	\$ 50,000,000

Item 3. Defaults Upon Senior Securities.

None.

Item 4. (Removed and Reserved).**Item 5. Other Information.**

None

Item 6. Exhibits.

- 3.2 Restated By-laws (previously filed as Exhibit 3.1 to the Current Report on Form 8-K filed on February 28, 2011 (File No. 0-26642) and incorporated herein by reference)
- 10.1+ Accelerated Share Repurchase Program Agreement, dated March 1, 2011, by and between J.P. Morgan Securities LLC, as agent for JPMorgan Chase Bank, National Association, London Branch and Myriad Genetics, Inc.
- 31.1 Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

Table of Contents

- 32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101@ The following materials from Myriad Genetics, Inc. s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets, (ii) the unaudited Condensed Consolidated Statements of Income, (iii) the unaudited Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.
- + Confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.
- @ Users of the XBRL data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MYRIAD GENETICS, INC.

Date: May 4, 2011

By: /s/ Peter D. Meldrum
Peter D. Meldrum
President and Chief Executive Officer
(Principal executive officer)

Date: May 4, 2011

By: /s/ James S. Evans
James S. Evans
Chief Financial Officer
(Principal financial and chief accounting officer)